With the limited number of available surface targets specific to cancer cells, the ability to efficiently target cancer-specific intracellular proteins presented on pMHC has become more desirable and recently validated with KIMMTRAKs approval by FDA of the first bispecific peptide-HLA-directed CD3 T cell engager targeting gp100 in melanoma. The gene discussed is PMEL; the disease is cancer.